News & Insights

Markets
AZN

AstraZeneca: European Commission Approves Qtrilmet For Type-2 Diabetes

November 15, 2019 — 02:23 am EST

Written by RTTNews.com for RTTNews ->

(RTTNews) - AstraZeneca (AZN.L, AZN) reported that the European Commission has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes. The EC has approved Qtrilmet to improve glycaemic control in adults with type-2 diabetes when metformin with or without sulphonylurea and either Onglyza or Forxiga does not provide adequate glycaemic control, or when type-2 diabetes patients are already being treated with metformin, Onglyza and Forxiga.

Qtrilmet was approved in the US in May 2019 under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

AZN

More Related Articles

Info icon

This data feed is not available at this time.

  • •

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.